Skip To Main Content
Edward Mena on Muck Rack

Edward Mena

As seen in: Nature, HCP Live

Get in touch with Edward

Contact Edward, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms

|
By Natalie Cook, Anthony B El-Khoueiry, David J. Pinato, Nguyen Tran, David Hsiehchen, Edward Mena, Tim Meyer, Jincao Wu, Shriram M. Pathak, Costanza Paoletti, Chinyere E. Okpara, Juanita Lopez, T. R. Jeffry Evans, Lea Dutta
| Nature Verified
Abstract We present data from the Phase 1 open-label Study 101 of E7386, an oral protein-protein interaction inhibitor reported to block the CBP/β-catenin interaction, in patients with solid tumours. Eligible patients (across the UK and US) aged ≥18 years had advanced/recurrent solid tumours (dose-escalation) or CTNNB1-mutated hepatocellular carcinoma (dose-expansion). Primary objectives were to assess safety/tolerability and determine the recommended Phase 2 dose (RP2D) of E7386.
Open in Who Shared Issue with article?

Unmet Needs in the Treatment of PBC

|
By Kris V. Kowdley, Steven Flamm, Edward Mena, David Victor III
| consultantlive.com
Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD: We’re comingto the end of this discussion, but I want to talk about unmet needs in PBC [primary biliary cholangitis]. What are some unmet needs? I’m going to have everyone comment, but I’m going to start with you, David. David Victor III, MD: This was a lead-in to say that transplantation for patients with PBC is an unmet need.
Open in Who Shared View Duplicates (2) Issue with article?

Emerging Treatment Options in PBC

|
By Kris V. Kowdley, Steven Flamm, Edward Mena, David Victor III
| consultantlive.com
Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD: There are a lot of new things, like new medications in development. Seladelpar is in a phase 3 trial that’s close to enrollment. Elafibranor is in a phase 3 trial that’s close to enrollment. These are PPAR-Δ and PPAR-⍺-Δ dual agonists. Saroglitazar, which is an PPAR-⍺-γ dual agonist, is also in clinical trials. There’s a fixed-dose combination study that’s ongoing with obeticholic acid and bezafibrate. Sonal, what’s your impression about these trials?
Open in Who Shared View Duplicates (2) Issue with article?
See all 18 licensed articles (35 Total)